Chase's Story

Cookie Notification

We use cookies to collect information about how our website is used and to improve the visitor experience. You can change your browser's cookie settings at any time. Please review our privacy policy for more information. OK

In September 2014, Chase, 6 years old, started seizing. The seizures didn’t stop.

He was treated at the pediatric intensive care unit at Children’s Hospital of Philadelphia where they tried to stop the seizures, but could not.

Extensive tests were run, but no answers.

After two weeks, Chase was diagnosed with FIRES (Febrile Infection-Related Epilepsy Syndrome). FIRES is a rare, catastrophic form of epilepsy which is characterized by acute onset of drug-resistant status epilepticus (continuous seizures) in previously healthy child

High dose phenobarbital treatment finally broke his status epilepticus after 14 days, but Chase continued having many seizures every day.

Chase was approved for Epidiolex treatment through GW’s innovative compassionate use program.

“Chase remains on Epidiolex.  We are so grateful for the opportunity to try this experimental medicine and are eagerly following GW’s progress to bring this medicine to other epilepsy patients”

Olivia  (Chase’s mom)